BIIB033 (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1.
As of 2015 it was being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.
[1][2][3] Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.